Master Files with ectd
|
|
- Henry Owens
- 6 years ago
- Views:
Transcription
1 Master Files with ectd Follow-up Information Meeting Step 2 Dr. Christoph Berger August 31, 2010 Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern
2 Overview 1. Master Files in general 2. Drug Master Files 3. Plasma Master Files 4. Conclusions 2
3 Master Files Swissmedic There are three types of Master Files: Drug Master Files (DMF) Plasma Master Files (PMF) Vaccine Antigen Master Files (VAMF) so far not submitted at Swissmedic 3
4 Submission of Master Files Submitted by DMF/PMF holder Along with an application by MAH New application NAS (ZL101) Variations requiring notification (ZL301) Variations requiring authorisation (ZL302) Once ectd, always ectd DMF/PMF submission should not precede submission of drug product documentation CDs/DVDs for paper submission are welcome 4
5 Overall principle of submitting sequences Example of life cycle management of Master File Sequence Initial application Responses to questions 0002 Responses to pre-decision Variation 1 Responses to questions 0005 Variation 2 5
6 Status Master Files / Documentation of Applicant Hybrids paper / ectd are possible: DMF/PMF ectd Paper DMF/PMF ectd Paper DMF/PMF Drug product documentation ectd ectd Paper P-Doc Paper P-Doc 6
7 Overview 1. Master Files in general 2. Drug Master Files 3. Plasma Master Files 4. Conclusions 7
8 Drug Master Files DMF Principle: The Master File is a stand alone dossier (own life cycle) Electronic submissions for DMFs should be in the ectd format Consists of restricted part (RP), applicant part (AP), Cover Letter, Letter of Access, Swissmedic forms Submission of baseline for DMF/PMF without concurrent variation is possible A consolidation sequence has to be submitted if necessary Generally: Envelope and M1 according to Swiss Module 1 Specification 8
9 DMF Envelope Element invented name Perfesub (Farma SA) Element application type = dmf Element submission description indicate version no Element related ectd Sequence refers to DMF/PMF life cycle For elements related exclusively to final product n/a (e.g. galenic form) Element applicant n/a (information is given using Form DMF) For a variation of a DMF/PMF the element application type should indicate supplemental-info 9
10 Example DMF Envelope 10
11 DMF - Module 1 The country code should be used Module 1 CH Cover letter has always life cycle operator new Form DMF for first Authorisation and Variations (M ) is to be included in the life cycle of the DMF and the life cycle of the drug product. Part A is filled in by the applicant (MAH), a copy of it is transferred to the DMF holder, the form gets completed by filling in Part B by the DMF Holder. Letter of Access (M ) is to be included in the life cycle of the DMF and the life cycle of the drug product. Signed paper copies of Letter of Access and Form DMF for first Authorisation and Variation must be provided. 11
12 DMF - Module 1/2/3 The prefix RP or AP should be added to <substance> metadata value, every leaf title in the respective section (RP=Restricted Part, AP=Applicant Part). It is also recommended to add RP or AP to the file names. Documents that are the same in both the AP and RP sections should be included only once and placed in the AP section of the folder structure. The leaf in the RP section will therefore point to the file in the AP section folder. 12
13 Example DMF Module (I) 13
14 Example DMF Module (II) 14
15 Overview 1. Master Files in general 2. Drug Master Files 3. Plasma Master Files 4. Conclusions 15
16 Plasma Master Files PMF (I) Principle: The Master File is a stand alone dossier (own life cycle) Electronic submissions for PMFs should be in the ectd format Annual updates Expert statement to be put under Module 2.3 of the drug product 16
17 Plasma Master Files PMF (II) Documentation to be provided Generally: Envelope and M1 according to Swiss Module 1 Specification Signed declaration that the PMF dossier and the certificate can be applied to the drug product M1 Additional information Copy of the EMA PMF certificate (without annexes) M Copy of the EMA evaluation report M1.7.2 Complete documentation for Module 2.3 and 3 is needed, also when there is a EMA evaluation report 17
18 Overview 1. Master Files in general 2. Drug Master Files 3. Plasma Master Files 4. Conclusions 18
19 Conclusions Swissmedic is ready to accept new DMF/PMF and variations to DMF/PMF (step 2 of SIMES) Timelines remain unchanged There is still limited experience with ectd of DMF/PMF In case of questions, please contact Swissmedic (esubmission@swissmedic.ch) 19
20 Thank you for your attention! 20
Guideline on influenza vaccines submission and procedural requirements
1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module
More informationProcedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure
1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza
More informationREGULATORY AFFAIRS UNIVERSITY JOINS INDUSTRY - BARCELONA MARCH 15 TH, 2017 GALENICUM REGULAOTRY AFFAIRS 1
REGULATORY AFFAIRS UNIVERSITY JOINS INDUSTRY - BARCELONA MARCH 15 TH, 2017 GALENICUM REGULAOTRY AFFAIRS 1 Introduction Regulatory Affairs-Europe Regulatory Affairs-other markets Career development & personal
More informationGuidance on the GLP Requirements for Peer Review of Histopathology Advisory Document
GLP Roundtable 2014 Guidance on the GLP Requirements for Peer Review of Histopathology Advisory Document Dr. Elisabeth Klenke, Head Preclinical Review and GLP Monitoring Compliance Unit Swissmedic Swiss
More informationSeminar für Wissenschaftsjournalisten «Krebszellen mit dem Immunsystem bekämpfen»
Zürich, 15. März 2017 Stiftung zum Glockenhaus Seminar für Wissenschaftsjournalisten «Krebszellen mit dem Immunsystem bekämpfen» Herausforderungen in der Zulassung mit der Präzisionsmedizin Claus Bolte,
More informationStandard operating procedure
Standard operating procedure Title: Article 29(4) referral procedures (MRP/DCP referrals) Status: PUBLIC Document no.: SOP/H/3177 Lead author Approver Effective date: 04-SEP-12 Name: Thomas Larsson Name:
More informationRisk Management Plan Summary
Risk Management Plan Summary Terrosa Teriparatide 20 micrograms/80 microliters Solution for injection Document Version: 1.0 Document Date: 24.01.2019. Based on EU RMP Version: 1.2 Marketing Authorization
More informationGuideline on the processing of renewals in the centralised procedure
14 July 2016 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation December 2000
More informationProper CMC Submission -API. Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD
Proper CMC Submission -API Ramnarayan Randad, Ph.D. DMF Review Staff/OGD June 4, 2014 GPhA/FDA Bethesda, MD 1 Type II Drug Master Files (DMFs) and GDUFA Generic Drug User Fee Amendments (GDUFA) July 9,
More informationMedicinal Products for Human Use HOMEOPATHIC MEDCINAL PRODUCT FOR HUMAN USE. December 2005
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/BL D(2005) NOTICE TO APPLICANTS Medicinal Products for Human Use VOLUME 2B Presentation and content
More informationUpdate regarding PSUR and RMP for herbal and homeopathical medicinal products
Update regarding PSUR and RMP for herbal and homeopathical medicinal products Mag. Dr. Irmgard Resch Dept. Pharmacovigilance AGES-Gespräche 11.11.2014 www.basg.gv.at Österreichische Agentur für Gesundheit
More informationSUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA
SUMMARY OF THE RISK MANAGEMENT PLAN (CH) VELTASSA Active Substance: Anatomical Therapeutic Code: MAH or Applicant: Medicinal Product(s) to Which this RMP Refers: Products Concerned (Brand Names): Patiromer
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. Brussels, Revision 1. Medicinal Products for Human Use
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Brussels, Revision 1 NOTICE TO APPLICANTS Medicinal Products for Human Use VOLUME 2B Presentation
More informationSummary of the Risk Management Plan (RMP) for Vizamyl (flutemetamol 18 F)
Summary of the Risk Management Plan (RMP) for Vizamyl (flutemetamol 18 F) Version 1 October 2016 Disclaimer: The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application
More informationGDUFA: 2 ½ years later Impact & Importance
GDUFA: 2 ½ years later Impact & Importance Georgia Hizon Manager, Regulatory Publications Fresenius Kabi USA, LLC Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationMHRA Pharmacovigilance System Master File (PSMF) Inspection Findings
MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings Gretel Sakyi Medical Information and Patient Safety Manager AstraZeneca UK 07 June 2018 Agenda MHRA inspections How inspectors use the
More informationATMPs & EU GMP Update. Bryan J Wright July 2017
ATMPs & EU GMP Update Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline ATMPs What they are? Why are we looking at this subject? The Licensing position of ATMPs and use of PRIME ATMPs and GMP Inspections
More informationWhat is the focus of clinical review?
Workshop Radiopharmaceuticals, Bern, 12. September 2018 What is the focus of clinical review? Wild Damian, Mitglied Fachkommission für Radiopharmazeutika FKRP, Abteilungsleiter Nuklearmedizin Universitätsspital
More informationUPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS DDL2017 6-8 December 2017 Presented by Claudia Vincenzi on 7 December 2017 Quality Office EMA An agency of the European
More informationRisk Management Plan Summary
Risk Management Plan Summary TREMFYA (guselkumab) 100 mg/ml pre-filled syringe Document Version: 1.0 (11.07.2018) Based on EU RMP version 1.2 Marketing authorization holder: Janssen-Cilag AG, Gubelstr.
More informationCHAPTER 3. Union Referral Procedures MAY 2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Brussels, Revision May 2014 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation
More informationMHRA Pharmacovigilance Inspections: Prepare and Manage for Success
MHRA Pharmacovigilance Inspections: Prepare and Manage for Success Created and Presented by Miranda Dollen Vice President, Pharmacovigilance & EEA QPPV Mapi 2016, All Rights Reserved 2 Prepare and Manage
More informationPrevention of TACO what Haemovigilance data tell us
Prevention of TACO what Haemovigilance data tell us Swisstransfusion, Genève 6. Septembre 03 Markus Jutzi, Morven Rüesch Clinical Reviewer Haemovigilance, Swissmedic Swissmedic Schweizerisches Heilmittelinstitut
More informationSUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE
SUBMISSION OF COMMENTS ON DRAFT COMMISSION PAEDIATRICS GUIDELINE COMMENTS FROM Astellas Pharma Europe BV, Elisabethhof 19, 2353EW Leiderdorp, The Netherlands GENERAL COMMENTS A guiding document on the
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationPractical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings
Version 2 Updated on 29/11/2011 Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings Valid as of: 11 September 2011 Disclaimer: This
More informationVARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014
Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
SOP details SOP title: SOP number: SOP category: Version number: 03 Version date: 19 December 2016 Effective date: 19 January 2017 Revision due date: 19 January 2020 NEWCASTLE CLINICAL TRIALS UNIT STANDARD
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 July 2006 Doc. Ref. EMEA/186279/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON LEGAL STATUS FOR THE SUPPLY TO THE PATIENT OF CENTRALLY AUTHORISED
More informationGuidance on Drug Master File System in Japan
2 nd China Japan Symposium on Drug Development focusing on IND, Pre Consultation, ti GMP and DMF System March 29, 2011 in Beijing Guidance on Drug Master File System in Japan Takashi YOSHITANI, Ph.D. Master
More informationSummary of Risk Management Plan (RMP)
Summary of Risk Management Plan (RMP) Neuraceq Florbetaben ( 18 F), solution for injection SWAN Isotopen AG CH-3010 Bern The Risk Management Plan (RMP) is a comprehensive document submitted as part of
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS
European Medicines Agency Evaluation of Medicines for Human Use London, 20 May 2009 Doc. Ref. EMEA/CPMP/BWP/125/04 Rev.1 Appendices COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT APPENDICES
More informationTitle: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use)
European Medicines Agency Standard Operating Procedure Title: Handling of a request for accelerated assessment of initial marketing authorisation applications (human use) PUBLIC Document no.: SOP/H/3182
More informationIndustry s Perspective on the Status of Medical Device Regulations. FUNDISA Workshop 09 & 10 Oct Anele Vutha SAMED Regulatory Committee
Industry s Perspective on the Status of Medical Device Regulations FUNDISA Workshop 09 & 10 Oct 2014 Anele Vutha SAMED Regulatory Committee Today s Topics: 1. Medical Device Definition - Differences 2.
More informationGMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY
GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY Dr. Christian Schärer Swissmedic, Swiss Agency for Therapeutic Products Inspectorates, Hallerstrasse 7 CH-3000 Bern 9 christian.schaerer@swissmedic.ch
More informationMedicinal Product no longer authorised
MAJOR CHANGES 1 Procedural steps taken and scientific information after the authorisation Trudexa No Scope Opinion issued on Commission Decision II/0037 Update of of Characteristics To update section 5.1
More informationCHMP Type II variation assessment report
26 January 2017 EMA/CHMP/59238/2017 Invented name: Avastin International non-proprietary name: bevacizumab Procedure No. EMEA/H/C/000582/II/0093 Marketing authorisation holder (MAH): Roche Registration
More informationStandard operating procedure
Standard operating procedure Title: Preparation of an initial European Public Assessment Report (EPAR) for a human medicinal product following positive or negative opinion Status: PUBLIC Document no.:
More informationStandard operating procedure
Standard operating procedure Title: CHMP/CAT/PRAC rapporteur/co-rapporteur/peer reviewer appointment in the centralised procedure Status: PUBLIC Document no.: SOP/H/3143 Lead author Approver Effective
More informationCHAPTER 3. September 2007
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/SM D(2007) Revision September 2007 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing
More informationDecentralised Procedure. Public Assessment Report. Memantin Orion 10/20 mg Filmtabletten. Memantine hydrochloride DE/H/3653/ /DC
Decentralised Procedure Public Assessment Report Memantin Orion 10/20 mg Filmtabletten Memantine hydrochloride DE/H/3653/001-002/DC Applicant: Orion Corporation, Finland Reference Member State DE TABLE
More informationSOP-QA-30 V Scope
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Joanne Rodger, Senior R&D Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys,
More informationDecentralised Procedure. Public Assessment Report. Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten. Metamizole sodium monohydrate
Decentralised Procedure Public Assessment Report Metamizol Midas / Metamizol STADA / Mimetanal 500 mg Tabletten Metamizole sodium monohydrate DE/H/4091-4093/001/DC Applicant: Midas Pharma GmbH, Germany
More informationDecentralised Procedure. Public Assessment Report. ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC
Decentralised Procedure Public Assessment Report ALGOTRA 37.5 mg/325 mg überzogene Tabletten Tramadol/Paracetamol DE/H/3688/001/DC Applicant: Laboratoires SMB S.A. Reference Member State DE TABLE OF CONTENTS
More informationResponse to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the
Response to: Concept paper of 9 February 2011 submitted for public consultation by the European Commission on the REVISION OF THE CLINICAL TRIALS DIRECTIVE 2001/20/EC Submitted by the European AIDS Treatment
More informationBlanka Hirschlerová. EDQM CEP conference Prague, Czech Republic
1 Experience with CEPs from a European regulatory authority perspective Blanka Hirschlerová EDQM CEP conference Prague, Czech Republic 2012 STATE INSTITUTE FOR DRUG CONTROL Agenda 2 Agenda Introduction
More informationPart I Overview: The Master Club Manager (MCM) Program
Part I Overview: The Master Club Manager (MCM) Program A certification and recognition program for a special group of professionals who have made extraordinary and long-lasting contributions to the club
More informationFasenra. 30 mg, solution for injection. Summary of the Risk Management Plan (RMP) for Fasenra (Benralizumab)
Fasenra 30 mg, solution for injection Summary of the Risk Management Plan (RMP) for Fasenra (Benralizumab) Document Version: 1.0 Document Date: 08-June-2018 Summary of the risk management plan (RMP) for
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 08/03/2018 n/a
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationMaviret (Glecaprevir / Pibrentasvir)
Swiss Summary of the Risk Management Plan (RMP) Maviret (Glecaprevir / Pibrentasvir) 100 mg/40 mg Film-coated tablets Version 1.0 (Dec 2016) AbbVie AG 1 Disclaimer The Risk Management Plan (RMP) is a comprehensive
More informationVaccine assessment for prequalification
Vaccine assessment for prequalification Briefing on Vaccine Prequalification for manufacturers DCVMN meeting, Kunming, China, 13 March 2016 Olivier Lapujade World Health Organization, EMP/RHT/PQT lapujadeo@who.int
More informationSwitzerland - still a special country?
5 th Pharmacovigilance Forum GLC Switzerland - still a special country? Tips for an successful Pharmacovigilance Inspection Dr. Doris Taeschner, Boehringer Ingelheim (Schweiz) GmbH 2 nd March 2017 Berlin
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM
More information(Invented) name Strength. Leflunomide Apotex 10 mg Tablet Oral use. Leflunomide Apotex 20 mg Tablet Oral use
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 1 Member State EU/EEA Marketing authorisation
More informationSwiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)
Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide) RMP Summary: Version 1, November 2017 EU RMP: Version 1.0, November 2016 Page 1 of 6 The Risk Management Plan (RMP) is a comprehensive
More informationTGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview
IPFA Workshop Session 7: REGULATORY CONSIDERATIONS TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview Mary Lavithis, CSL Behring Australia Presented at: IPFA Asia
More informationEuropean Medicines Agency decision
EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)
More informationTherapeutic Use Exemption (TUE) Policy
Therapeutic Use Exemption (TUE) Policy Following an amendment to the Irish Anti-Doping Rules by the Council on 6th April 2010, the Irish Sports Council has established a Therapeutic Use Exemption (TUE)
More informationCompleteness Assessments for Type II API DMFs Under GDUFA Guidance for Industry
Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)
More informationOFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.3 OFFICE OF PHARMACEUTICAL SCIENCES COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS PURPOSE
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationMedication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski
Medication errors Impact of medication error guidance and regulation on drug-device combination products June 2017 Dan Wozinski Agenda Understand the management of medication errors within global requirements
More informationNOTICE TO APPLICANTS
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Food and feed safety, innovation Animal nutrition, veterinary medicines NOTICE TO APPLICANTS VETERINARY MEDICINAL PRODUCTS VOLUME 6A Procedures
More informationTOBACCO CONTROL PROGRAM COMMUNITY GRANT. REQUEST FOR PROPOSALS- Release Date: October 2, 2018 Application Deadline: October 19, 2018 at 5:00 PM
TOBACCO CONTROL PROGRAM COMMUNITY GRANT REQUEST FOR PROPOSALS- Release Date: October 2, 2018 Application Deadline: October 19, 2018 at 5:00 PM PURPOSE Build capacity of Alameda County residents to participate
More informationVOLUME 6A Procedures for marketing authorisation
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 27.09.2007 ENTR/F2/KK D(2007) Revision September 2007 NOTICE TO APPLICANTS VETERINARY MEDICINAL
More informationEFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS
EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS Last updated (Rev.): 21 December 2007 Publication Date: 14 March 2007 NOTES
More informationEuropean Medicines Agency decision
EMA/279562/2017 European Medicines Agency decision P/0129/2017 of 8 May 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Split influenza virus, inactivated containing
More informationLionbridge Connector for Hybris. User Guide
Lionbridge Connector for Hybris User Guide Version 2.1.0 November 24, 2017 Copyright Copyright 2017 Lionbridge Technologies, Inc. All rights reserved. Published in the USA. March, 2016. Lionbridge and
More informationEuropean Medicines Agency decision
EMA/43440/2014 European Medicines Agency decision P/0046/2014 of 7 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (EMEA- 000498-PIP01-08-M02)
More informationDecentralised Procedure. Public Assessment Report. Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten. Lorazepam DE/H/4558/ /DC
Decentralised Procedure Public Assessment Report Lorazepam-neuraxpharm 1/ 2,5 mg Schmelztabletten Lorazepam DE/H/4558/001-002/DC Applicant: neuraxpharm Arzneimittel GmbH, Germany Reference Member State
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for ibuprofen
More informationREGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.
REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.
More informationMahoning County Public Health. Epidemiology Response Annex
Mahoning County Public Health Epidemiology Response Annex Created: May 2006 Updated: February 2015 Mahoning County Public Health Epidemiology Response Annex Table of Contents Epidemiology Response Document
More informationDecentralised Procedure. Public Assessment Report. Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten
Decentralised Procedure Public Assessment Report Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten Pramipexole dihydrochloride monohydrate DE/H/4703/001-007/DC Applicant:
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, March 2018 SANTE-2017-11668 Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment
More informationInitial (Full) Marketing Authorisation application accelerated assessment timetables
30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European
More informationExpedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines
Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Preamble On 11 June 2009, WHO declared an influenza pandemic caused by influenza A (H1N1) 2009 virus 1. On 13 July 2009, WHO
More informationEuropean Medicines Agency decision
EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)
More informationProcedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products
25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of
More informationEuropean Medicines Agency decision
EMA/785816/2015 European Medicines Agency decision P/0294/2015 of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationUKALL14 DRUG SUPPLY GUIDELINES
CONTACT DETAILS UKALL14 DRUG SUPPLY GUIDELINES For further information on trial drugs, trial protocol, dosing, supply drug and distribution queries please contact: UKALL14 Trial Team Phone: 0207 679 9860
More informationSupport to paediatric medicines development
Support to paediatric medicines development SME Info day Supporting innovative medicines development and early access Presented by Rocio Fernandez Human Medicines Research & Development Support Division
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Clozapin Regiomedica 50 mg/ml Suspension zum Einnehmen Clozamedica 50 mg/ml Suspension zum Einnehmen
More informationCYCLE Vanguard: Flow Sheet for Protocol Schedule of Forms + Procedures. Binder Title and Cover Pages. Required Materials Study Schema RC flowsheet
Binder Title and Cover Pages Required Materials Study Schema flowsheet 1 1. Screening a. Screen patient for eligibility. ASAP after ICU admission (within 4 days of mechanical ventilation and 7 days of
More informationClay Tablet Connector for hybris. User Guide. Version 1.5.0
Clay Tablet Connector for hybris User Guide Version 1.5.0 August 4, 2016 Copyright Copyright 2005-2016 Clay Tablet Technologies Inc. All rights reserved. All rights reserved. This document and its content
More informationBlueBayCT - Warfarin User Guide
BlueBayCT - Warfarin User Guide December 2012 Help Desk 0845 5211241 Contents Getting Started... 1 Before you start... 1 About this guide... 1 Conventions... 1 Notes... 1 Warfarin Management... 2 New INR/Warfarin
More informationPCN-ISO GEN Requirements for the Qualification of personnel for Limited Applications of Non-destructive Testing
Certification Services Division The Newton Building St. George s Avenue Northampton NN2 6JB Tel: +44(0)1604-893-811. Fax: +44(0)1604-893-868. E-mail: pcn@bindt.org PCN-ISO 20807-GEN Requirements for the
More informationWEdoc: Therapy Documentation System Basics
WEdoc: Therapy Documentation System Basics Complete Insurance Verification Request Form (Form may be found on Website) Select Employees Select Payroll Website Enter username and password Select Forms Select
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationAnnual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs
R&D Department Annual Progress and Safety Reporting SOP for HEY-sponsored CTIMPs Hull and East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationAnnex II - List of enforceable provisions of REACH and CLP
Annex II - List of enforceable provisions of REACH and CLP The provisions below are listed according to the sections of the main report, together with the Titles of the Regulation in the case of REACH.
More informationJune For 2010, Swissmedic compiled annual pharmacovigilance statistics in the following sectors:
June 2011 In this issue: Local anaesthetics and MetHb 3 Rosiglitazone 4 New: Vaccinovigilance14 DIA EuroMeeting 27 Contacts 33 I: Editorial 1 II: Flash: Signals relating to the safety of medicines from
More informationMODIFICATION OF APPLICATION TO BECOME A LICENSED PRODUCER UNDER THE ACCESS TO CANNABIS FOR MEDICAL PURPOSES REGULATIONS
MODIFICATION OF APPLICATION TO BECOME A LICENSED PRODUCER UNDER THE ACCESS TO CANNABIS FOR MEDICAL PURPOSES REGULATIONS (ACMPR) (Disponible en français) This form should be used if you already submitted
More informationAdministrative guidance to applicants on the preparation and presentation of applications for authorisation of additives for use in animal nutrition
FEED UNIT GUIDANCE OF EFSA Administrative guidance to applicants on the preparation and presentation of applications for authorisation of additives for use in animal nutrition Issued in September 2008
More informationEuropean Medicines Agency decision
EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for cefoperazone/sulbactam
More informationEuropean Medicines Agency decision
EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)
More informationEPAR type II grouped variation for Improvac
10 November 2010 EMA/41755/2011 EPAR type II grouped variation for Improvac (Gonadotropin releasing factor (GnRF) analogue-protein conjugate) EMEA/V/C/136/II/007/G Scope: Type II Addition of behaviour
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, Draft Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment and information
More information